GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Retail - Defensive » X Bioscience PCL (BKK:XBIO-W7) » Definitions » Cyclically Adjusted Revenue per Share

X Bioscience PCL (BKK:XBIO-W7) Cyclically Adjusted Revenue per Share : ฿0.00 (As of Mar. 2025)


View and export this data going back to 2025. Start your Free Trial

What is X Bioscience PCL Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

X Bioscience PCL's adjusted revenue per share for the three months ended in Mar. 2025 was ฿0.044. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ฿0.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, X Bioscience PCL's average Cyclically Adjusted Revenue Growth Rate was -25.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -18.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of X Bioscience PCL was -8.60% per year. The lowest was -18.00% per year. And the median was -10.80% per year.

As of today (2025-07-10), X Bioscience PCL's current stock price is ฿0.02. X Bioscience PCL's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ฿0.00. X Bioscience PCL's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of X Bioscience PCL was 1.86. The lowest was 0.01. And the median was 0.14.


X Bioscience PCL Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for X Bioscience PCL's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X Bioscience PCL Cyclically Adjusted Revenue per Share Chart

X Bioscience PCL Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

X Bioscience PCL Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of X Bioscience PCL's Cyclically Adjusted Revenue per Share

For the Food Distribution subindustry, X Bioscience PCL's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


X Bioscience PCL's Cyclically Adjusted PS Ratio Distribution in the Retail - Defensive Industry

For the Retail - Defensive industry and Consumer Defensive sector, X Bioscience PCL's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where X Bioscience PCL's Cyclically Adjusted PS Ratio falls into.


;
;

X Bioscience PCL Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, X Bioscience PCL's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.044/134.9266*134.9266
=0.044

Current CPI (Mar. 2025) = 134.9266.

X Bioscience PCL Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 9.810 100.684 13.146
201509 5.744 100.392 7.720
201512 7.629 99.792 10.315
201603 8.481 100.470 11.390
201606 9.073 101.688 12.039
201609 7.205 101.861 9.544
201612 6.658 101.863 8.819
201703 7.201 102.862 9.446
201706 14.853 103.349 19.391
201709 6.906 104.136 8.948
201712 4.844 104.011 6.284
201803 4.143 105.290 5.309
201806 4.274 106.317 5.424
201809 4.960 106.507 6.284
201812 4.737 105.998 6.030
201903 1.612 107.251 2.028
201906 2.031 108.070 2.536
201909 2.271 108.329 2.829
201912 2.155 108.420 2.682
202003 2.056 108.902 2.547
202006 2.763 108.767 3.428
202009 0.159 109.815 0.195
202012 0.098 109.897 0.120
202103 0.092 111.754 0.111
202106 0.100 114.631 0.118
202109 0.099 115.734 0.115
202112 -0.018 117.630 -0.021
202203 0.092 121.301 0.102
202206 0.103 125.017 0.111
202209 0.095 125.227 0.102
202212 0.113 125.222 0.122
202303 0.094 127.348 0.100
202306 0.089 128.729 0.093
202309 0.084 129.860 0.087
202312 0.071 129.419 0.074
202403 0.070 131.776 0.072
202406 0.066 132.554 0.067
202409 0.163 133.029 0.165
202412 0.070 133.157 0.071
202503 0.044 134.927 0.044

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


X Bioscience PCL  (BKK:XBIO-W7) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of X Bioscience PCL was 1.86. The lowest was 0.01. And the median was 0.14.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


X Bioscience PCL Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of X Bioscience PCL's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


X Bioscience PCL Business Description

Traded in Other Exchanges
Address
Phahon Yothin Road, No.304, Room No.1803-1806, 18th Floor, Vanit Place Aree Tower (Tower A, Sam Sen Nai, Bangkok, THA, 10400
X Bioscience PCL is engaged in investment in food and beverages business and the group are engaged in selling food and beverages, and manufacturing and selling biological products. The group operates in two business segments: the food and beverage sales segment and the internal management services segment provided by the parent company. The group operates in a single geographic area, which is Thailand. The company's brand consists of Kagonaya, Bake, and Leboeuf.

X Bioscience PCL Headlines

No Headlines